306 related articles for article (PubMed ID: 17143831)
1. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
[TBL] [Abstract][Full Text] [Related]
2. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Avihingsanon A; Manosuthi W; Kantipong P; Chuchotaworn C; Moolphate S; Sakornjun W; Gorowara M; Yamada N; Yanai H; Mitarai S; Ishikawa N; Cooper DA; Phanuphak P; Burger D; Ruxrungtham K
Antivir Ther; 2008; 13(4):529-36. PubMed ID: 18672531
[TBL] [Abstract][Full Text] [Related]
4. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Chang SY; Lin SW; Hung CC
Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
[No Abstract] [Full Text] [Related]
5. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
van Oosterhout JJ; Kumwenda JJ; Beadsworth M; Mateyu G; Longwe T; Burger DM; Zijlstra EE
Antivir Ther; 2007; 12(4):515-21. PubMed ID: 17668560
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
Prasitsuebsai W; Cressey TR; Capparelli E; Vanprapar N; Lapphra K; Chokephaibulkit K
Pediatr Infect Dis J; 2012 Apr; 31(4):389-91. PubMed ID: 22146740
[TBL] [Abstract][Full Text] [Related]
8. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Manosuthi W; Tantanathip P; Chimsuntorn S; Eampokarap B; Thongyen S; Nilkamhang S; Sungkanuparph S
Int J Infect Dis; 2010 Nov; 14(11):e1013-7. PubMed ID: 20880733
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
Maartens G; Decloedt E; Cohen K
Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
[TBL] [Abstract][Full Text] [Related]
11. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
12. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
McIlleron H; Ren Y; Nuttall J; Fairlie L; Rabie H; Cotton M; Eley B; Meyers T; Smith PJ; Merry C; Maartens G
Antivir Ther; 2011; 16(3):417-21. PubMed ID: 21555825
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Autar RS; Wit FW; Sankote J; Mahanontharit A; Anekthananon T; Mootsikapun P; Sujaikaew K; Cooper DA; Lange JM; Phanuphak P; Ruxrungtham K; Burger DM
Antivir Ther; 2005; 10(8):937-43. PubMed ID: 16430199
[TBL] [Abstract][Full Text] [Related]
16. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
[TBL] [Abstract][Full Text] [Related]
17. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
Burman WJ; Gallicano K; Peloquin C
Clin Infect Dis; 1999 Mar; 28(3):419-29; quiz 430. PubMed ID: 10194057
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
[TBL] [Abstract][Full Text] [Related]
20. Update on nevirapine: quest for a niche.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
